Published in Bioterrorism Week, October 11th, 2004
This nonexclusive license agreement allows Vaxin to use Crucell's PER.C6 cell line for the development, manufacture, and commercialization of its recombinant adenoviral vaccines against certain respiratory viruses.
Under the terms of the agreement, Crucell will receive an upfront payment, annual maintenance fees, and royalties on future sales. Further financial details were not disclosed.
"The PER.C6 technology is a well-established cell line that is utilized by leading pharmaceutical companies around the world," stated Frank...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Bioterrorism Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.